April 27, 2026-
Intellia Therapeutics has reported a landmark milestone for in vivo gene editing, announcing that its Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) met its primary endpoint and all key secondary endpoints, positioning the therapy as a potential first-in-class one-time treatment for hereditary angioedema (HAE).
The study marks a major inflection point not only for Intellia, but for the broader field of genetic medicines, representing the first Phase 3 success for an in vivo CRISPR therapy.
Lonvo-z is a single-dose CRISPR/Cas9 gene editing therapy delivered using a lipid nanoparticle (LNP) system. Rather than replacing a gene, lonvo-z permanently inactivates the KLKB1 gene in the liver, reducing kallikrein production and preventing the bradykinin-driven swelling attacks characteristic of HAE.
In the global randomized placebo-controlled Phase 3 study, a single infusion reduced attack rates by 87% versus placebo over the six-month efficacy period, while 62% of treated patients were completely attack-free and therapy-free, compared with just 11% in the placebo arm. Particularly notable, all patients receiving lonvo-z remained free from long-term prophylactic therapy at the data cutoff, reinforcing the potential for durable disease control after a single administration.
Safety data were also encouraging, with no serious adverse events reported in the treatment arm and most events limited to mild or moderate infusion-related reactions, headache, and fatigue.
The results support a potentially paradigm-shifting model in rare disease treatment: replacing chronic lifelong management with one-time genomic intervention.
Intellia has already initiated a rolling biologics license application with the FDA and is targeting a potential U.S. launch in the first half of 2027, if approved.
While lonvo-z uses LNP delivery rather than AAV, the success carries broader implications for the genetic medicine field, by further validating in vivo durable genomic medicines as a therapeutic class. Together, these platforms—AAV gene therapy, RNA medicines, and CRISPR editing—are increasingly converging toward one-time transformative treatments.
For the HAE field, where patients often face chronic injections or daily prophylaxis with breakthrough attacks still occurring, the possibility of lasting freedom from both attacks and ongoing therapy could represent a fundamental shift in standard of care.
